Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 65-70

  Mahadik, S P ^a,b   Shendarkar, N S ^a,b   Scheffer, R E ^c   Mukherjee, S ^a,b   Correnti, E E ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Dwight David Eisenhower Army Med C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID;

CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; LIPID METABOLISM; NORMAL HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SKIN FIBROBLAST;

EID: 0029783461     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90147-7     Document Type: Conference Paper

References (58)

1. Rotrosen J., Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. In: Meltzer H. Y., ed. Psychopharmacology. The Third Generation of Progress. New York: Raven Press, 1987; pp 759-764.
2. van Kammen D. P., Yao J. K., Goetz K. Polyunsaturated fatty acids, prostaglandins and schizophrenia. Ann NY Acad Sci 1989; 559: 411-424.
3. Horrobin D. F. The relationship between schizophrenia and essential fatty acids and eicosanoid metabolism. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 71-77.
4. Kaiya H., Horrobin D. F., Manku M. S., Morse-Fisher N. Essential and other fatty acids in plasma from schizophrenic and normal individuals from Japan. Biol Psychiatr 1991; 30: 357-362.
5. Bates C., Horrobin D. F., Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr Res 1992; 6: 1-7.
6. Keshavan M. S., Mallinger A. G., Pettegrew J. W., Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatr Res 1993; 49: 89-95.
7. Dougherty R. M., Galli C., Ferro-Luzzi A. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland and the USA. Am J Clin Nutr 1987; 45: 443-455.
8. Brenner R. R. Nutritional and hormonal factors influencing desaturation of essential fatty acids Prog Lipid Res 1991; 20: 41-47.
9. Szabo L., Lajko K., Barabas K., Matkovics B. Effects of neuroleptics on lipid peroxidation and peroxide metabolism enzyme activities in various discrete areas of the brain. Chem Pharmacol 1983; 14: 537-539.
10. Maziere C., Maziere J.-C., Mora L., Auclair M., Polonovski J. Trifluoperazine increases fatty acid turnover in phospholipids in cultured human fibroblasts. Lipids 1988; 23: 419-423.
11. Vaddadi K. S., Courtney P., Gilleard C. J., Manku M. S., Horrobin D. F. A double-blind trial of essential fatty acids supplimentation in patients with tardive dyskinesia. Psychiatr Res 1989; 27: 313-323.
12. Glen A. I. M., Glen E. M. T., Horrobin D. F., Vaddadi K. S., Spellman M., Morse-Fisher N., Ellis K., Skinne F. S. A red cell membrane abnormality in a sub-group of schizophrenic patients. Evidence for two diseases. Schizophr Res 1994; 12: 53-61.
13. Peet M., Horrobin D. F., Reynolds G. P. Arachidonic acid. a common link in the biology of schizophrenia. Arch Gen Psychiatr 1994; 5: 665-666.
14. Yao J. K., van Kammen D. P., Welker J. A., Gurklis J. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 1994; 13: 217-226.
15. Keshavan M. S., Pettegrew J. W., Panchalingam K., Kaplan D., Bozik E. 31p NMR spectroscopy detects altered brain metabolism before onset of schizophrenia. Arch Gen Psychiatr 1991; 48: 1112-1113.
16. Pettegrew J. W., Keshawan M. S., Panchalingam K. et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatr 1991; 48: 563-568.
17. Williamson P., Drost D., Stanley J., Carr T., Morrison S., Merskey H. Localized phosphorus 31 nuclear magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. Arch Gen Psychiatr 1991; 48: 578.
18. Horrobin D. F., Manku M. S., Hillman S., Iain A., Glen M. Fatty acid levels in brains of scizophrenics and normal controls. Biol Psychiatr 1991; 30: 795-805.
19. Weinberger D. R. Implications of normal brain developement for the pathogenesis of schizophrenia. Arch Gen Psychiatr 1987; 44: 660-669.
20. Nasrallah H. A. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr Clin 1993; 16: 269-280.
21. Kelkar H., Wakade C. G., Reddy R., Schnur D., Mukherjee S., Mahadik S. P. Altered membrane phospholipids in fibroblasts from schizophrenic patients. Biol Psychiatr 1993; 33: 99A.
22. Mahadik S. P., Mukherjee S., Correnti E. et al. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res 1994; 13: 239-247
23. Mukherjee S., Mahadik S. P., Horrobin D. F., Jenkins K., Correnti E., Scheffer R. Membrane fatty acid composition of fibroblasts from schizophrenic patients. Biol Psychiatr 1994; 35: 700.
24. Hagve T. A., Christensen E., Gronn M., Christophersen B. O. Regulation of the metabolism of polyunsaturated fatty acids. Scand J Clin Invest 1988; 48: 33-46.
25. Edelstein S. B., Breakenfield X. O. Human fibroblast cultures. In: Hanin I., Koslow S. H., eds. Physicochemical Methodologies and Psychiatric Research. New York: Raven Press, 1980: pp 200-243.
26. Mahadik S. P., Mukherjee S., Laev H., Reddy R., Schnur D. B. Abnormal growth and morphology of fibroblasts from schizophrenic patients. Psychiatr Res 1991; 37: 309-320.
27. Yorek M. A., Bohnker R. R., Spector A. A. Comparative utilization of n-3 polyunsaturated fatty acids by cultured human Y-79 retinoblastoma cells. Biochim Biophys Acta 1984; 795: 277-285.
28. Hagve T. A., Christophersen B. O. Evidence for retroconversion of adrenic acid (22:4 (n-6)) and docosahexaenoic acids (22:6 (n-3)) in isolated liver cells. Biochim Biophys Acta 1986; 875: 165-173.
29. Rosenthal M. D., Garcia M. C., Jones M. R., Sprecher H. Retroconversion and 4 desaturase of docosatetraenoate 22.4n-6 and docosapentaenoate 22.5n-3 by human cells in culture. Biochim Biophys Acta 1991; 1083: 29-36
30. Anderson G. J., Connor W. E., Corliss J. D. Docosahexaenoic acid is the prefered dietary fatty acid for the development of the brain. Pediatr Res 1990; 27: 89-97.
31. Wood R., Snyder F. Characterization and identification of glyceryl ether diesters present in tumor cells. J Lipid Res 1967; 8: 494-500.
32. Horrobin D. F., Glen A. I. M., Vaddadi K. S. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13: 195-208.
33. Hagve T. A., Christophersen B. O. Effects of dietary fats on arachidonic acid and eicosapentaenoic acid biosynthesis and conversion to C22 fatty acids in isolated liver cells. Biochim Biophys Acta 1984; 796: 205-217.
34. Mandon E. C., de Gomez-Dumm I. N. T. Biosynthesis of polyunsaturated fatty acids of n-6 & n-3 series in adrenocortical cells of rats. Effect of ACTH. Mol Cell Endocrinol 1989; 65: 175-185.
35. Pall H. S., Williams A. C., Blake D. R., Lunec J. Evidence of enhanced lipid peroxidation in cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; 2: 596-599.
36. Reddy R., Mahadik S. P., Murthy J. N., Mukherjee S. Enzymes of antioxident defence system in chronic schizophrenic patients. Biol Psychiatr 1991; 30: 409-412.
37. Peet M., Laugharne J., Rangarajan N., Renolds G. P. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993; 8: 151-153.
38. McCreadie R. G., MacDonald E., Wiles D., Campbell G., Paterson J. R. The nithsdale schizophrenia surveys XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects Br J Psychiatr 1995; 167: 1-8.
39. Mukherjee S., Mahadik S. P., Correnti E., Scheffer R., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1995; in press.
40. Mahadik S. P., Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia. Schizophr Res 1995; in press.
41. Gattaz W. F., Hubner C. K., Nevalainen T. J., Thuren T., Kinnunen P. K. J. Increased serum phospholipase A2 activity in schizophrenia: A replication study. Biol Psychiatr 1990; 28: 495-501.
42. Noponen M., Sanfilipo M., Samanich K. et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatr 1993; 34: 641-649.
43. Lohr J. B., Cadet J. L., Lohr M. A. et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanism. Schizophr Bull 1988; 14: 291-296.
44. Adler L. A., Peselo E., Rotrosen J. et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatr 1993; 150: 1405-1407
45. Mahadik S. P., Mukherjee S., Correnti E. E., Scheffer R. Elevated levels of lipid peroxidation products in plasma from drug-naive patient at the onset of psychosis. Schizophr Res 1995; 15: 66.
46. Mellor J. E., Laugharne J., Peet M. Eicosapentanoic acid and schizophrenia. Paper presented at the XIXth Collegium Internationale Neuropsycho-Pharmacologicum, Washington, DC, June 1994.
47. Christinsen O., Christinsen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78: 587-591.
48. Neuringer M., Connor W. E., Lin D. S., Barstad L., Luck S. Biochemical and functional effects of prenatal and postnatal ω3 fatty acid deficiancy on retina and brainin rhesus monkeys. Proc Natl Acad Sci USA 1986; 83: 402-4025.
49. Simopoulos A. P. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54: 438-463.
50. Wainwright P. E. Do essential fatty acids play a role in brain and behavioral development? Neurosci Biobehav Rev 1992; 16: 193-205.
51. Fish B., Marcus J., Hans S. L., Auerbach J. G., Perdue S. Infants at risk for schizophrenia. Sequelae of a genetic neurointegrative defect. Arch Gen Psychiatr 1992; 49: 221-235.
52. Bloom F. Advancing neurodevelopmental origin for schizophrenia. Arch Gen Psychiatr 1993; 50: 224-227
53. Axelrod J. Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction. Biochem Soc Trans 1990; 18: 503-507.
54. Dennis E. A., Rhee S.-G., Billah M. M., Hannum Y. A. Role of phospholipase in generating lipid second messenger signal transduction. FASEB J 1991; 5: 2068-2077
55. Farooqui A. A., Hirashima Y., Horrocks L. A. Brain phospholipases and their role in signal transduction. In: Bazan N., Toffano G., Murphy M., eds. Neurobiology of Essential Fatty Acids. New York: Plenum Press, 1992; pp 11-25.
56. Thomson G. A., ed. The Regulation of Membrane Lipid Metabolism. 2nd edn. New York: CRC Press, 1992.
57. Hudson C. J., Young L. T., Li P. P., Warsh J. J. CNS signal transduction in the pathophysiology and pharmacology of affective disorders and schizophrenia. Synapse 1993; 13: 278-293
58. Braff D. L. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull 1993; 19: 233-260.